Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    14736930 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Unknown  SORAVE - Sorafenib and Everolimus in Solid Tumors
Condition: Relapsed and/or Refractory Solid Tumors
Intervention: Drug: Combination of sorafenib and everolimus
2 Unknown  Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: erlotinib;   Procedure: FDG-/FLT-PET
3 Not yet recruiting A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
Condition: Carcinoma of the Lung.
Interventions: Drug: Binimetinib;   Drug: Pemetrexed;   Drug: Carboplatin

Indicates status has not been verified in more than two years